Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6848044 | 0.96 | GSK3B (0.43) | TERTHPGDPOLBGSK3BALDH1A1 | |
| SCHEMBL13562556 | 0.81 | KMT2A (0.61) | TERTHPGDPOLBALDH1A1MEN1 | |
| SCHEMBL6847320 | 0.81 | GSK3B (0.45) | HPGDPOLBGSK3BALDH1A1MEN1 | |
| SCHEMBL13518082 | 0.76 | HPGD (0.43) | HPGDPOLBGSK3BALDH1A1MEN1 | |
| SCHEMBL6847731 | 0.76 | KMT2A (0.60) | HPGDPOLBGSK3BALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL8821986 | 0.76 | PTGER4 (0.38) | HPGDPOLBGSK3BALDH1A1 | |
| SCHEMBL13562649 | 0.73 | TERT (0.50) | TERTHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL13519369 | 0.72 | GSK3B (0.50) | HPGDPOLBGSK3BALDH1A1MEN1 | |
| SCHEMBL6847165 | 0.72 | KMT2A (0.45) | HPGDPOLBGSK3BALDH1A1MEN1 | |
| SCHEMBL15988673 | 0.70 | GSK3B (0.73) | HPGDPOLBGSK3BALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937091-B2 | Inhibitor of protein crosslinking and use of the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2015-01-20 | — | — | US | disclosed |
| US-8937091-B2 | Inhibitor of protein crosslinking and use of the same | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2015-01-20 | — | — | US | disclosed |
| US-20120277423-A1 | PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME | JAPAN SCIENCE AND TECHNOLOGY AGENCY | 2012-11-01 | — | — | US | disclosed |
| WO-2011055561-A1 | PROTEIN CROSSLINKING INHIBITOR AND USE THEREOF | 独立行政法人科学技術振興機構 (JP) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277423-A1 | PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME | ARGLU1, F12, CDKL1 | TERT 2417/4885HPGD 1499/4885POLB 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.